Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rosnilimab - First Tracks Biotherapeutics

Next Previous
Drug Profile

Rosnilimab - First Tracks Biotherapeutics

Alternative Names: ANB-030

Latest Information Update: 07 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AnaptysBio
  • Developer First Tracks Biotherapeutics
  • Class Anti-inflammatories; Antibodies; Antirheumatics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Programmed cell death 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis
  • Discontinued Alopecia areata; Ulcerative colitis

Most Recent Events

  • 03 Jun 2026 Efficacy, pharmacodynamics and adverse event data from the phase IIb RENOIR trial in Rheumatoid arthritis presented at the 27th Annual Congress of the European League Against Rheumatism (EULAR-2026)
  • 14 May 2026 First Tracks Biotherapeutics completes an end-of-phase 2 meeting with the US FDA for Rheumatoid arthritis
  • 07 May 2026 Discontinued - Phase-II for Alopecia areata in USA (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top